Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Neoplasms 2Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms by Site 1Neoplasm, Residual 1Lung Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Bronchogenic 1

Interventions

Imatinib Mesylate 3fludarabine phosphate 2fludarabine 2Acetaminophen 2thymoglobulin 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Cyclophosphamide 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Blood Component Removal 1Azacitidine 1Antilymphocyte Serum 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Philadelphia Chromosome × Tyrosine Kinase Inhibitors × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡